FDA Panel Gets Varied Opinions on DTC Genomics | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Advisers for the US Food and Drug Administration this week heard arguments and recommendations about how it should approach direct-to-consumer genetic testing, with some parties making the case for little or no regulation, others seeking tighter controls, and some proposing a stratified regulatory scheme.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.